EF Hutton re-initiated coverage of VolitionRx with a Buy rating and $4.50 price target. The firm likes the “multi-prong approach and compelling platform to double-dip” into pet and human cancer screening and monitoring with blood tests for the “innovator” of affordable and efficient epigenetics diagnostics, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
